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This narrative review focuses on the herpes zoster (HZ) and its prevention in transplant 
patients. Varicella zoster virus (VZV) is highly contagious and distributed worldwide in 
humans. Primary VZV infection usually causes varicella and then establishes a lifelong 
latency in dorsal root ganglia. Reactivation of VZV leads to HZ and related complications 
such as postherpetic neuralgia. Age and decreased immunity against VZV are important 
risk factors for developing HZ. Transplant patients are at increased risk for developing 
HZ and related complications due to their immunocompromised status and the need 
for lifetime immunosuppression. Diagnosis of HZ in transplant patients is often clinically 
difficult, and VZV-specific antibodies should be determined by serologic testing to doc-
ument prior exposure to VZV during their pre-transplant evaluation process. Although 
antiviral agents are available, vaccination should be recommended for preventing HZ in 
transplant patients considering their complicated condition and weak organ function. 
Currently, there are two licensed HZ vaccines, of which one is a live-attenuated vaccine 
and the other is a HZ subunit vaccine. Both vaccines have shown promising safety and 
efficacy in transplants patients and especially the subunit vaccine could be administered 
post-transplant since this vaccine does not contain any live virus. Larger studies are 
needed about safety and immunogenicity of HZ vaccines in transplant populations, and 
extra efforts are needed to increase vaccine usage according to guidelines.
Keywords: varicella zoster virus, herpes zoster, postherpetic neuralgia, transplantation immunology, herpes 
zoster vaccine
Abbreviations: ACIP, Advisory Committee on Immunization Practices; AEs, adverse events; CDC, Centers for Disease 
Control and Prevention; CMI, cell-mediated immunity; CMV, cytomegalovirus; CSF, cerebrospinal fluid; DFA, direct 
immunofluorescent assay; ELISA, enzyme-linked immunosorbent assays; ESRD, end-stage renal disease; FAMA, fluorescent 
antibody to membrane antigen; FDA, Food and Drug Administration; gE, glycoprotein E; HCT, hematopoietic cell transplant; 
HSCT, hematopoietic stem cell transplant; HSV, herpes simplex virus; HZ, herpes zoster; HZ/su, herpes zoster subunit vac-
cine; IFNs, interferons; IgG, immune globulin G; JAK/STAT, Janus kinase-signal transducer and activator of transcription; 
JNK, C-Jun N-terminal kinase; LMP, lidocaine-medicated plasters; MMR, measles–mumps–rubella; PHN, postherpetic 
neuralgia; SOT, solid organ transplant; SPS, Shingles Prevention Study; STAT3, signal transducer and activator of transcrip-
tion 3; STPS/LTPS, Short-Term and Long-Term Persistence Substudy; TCAs, tricyclic antidepressants; TK, thymidine kinase; 
VZV, varicella zoster virus; VZIG, varicella-zoster immune globulin.
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iNTRODUCTiON
Varicella zoster virus (VZV) belongs to the Alphaherpesvirinae 
subfamily and is a member of the Varicellovirus genus. VZV 
is highly contagious and distributed worldwide in humans (1). 
Primary VZV infection usually occurs during childhood and 
causes varicella (chickenpox). Following infection by contact 
with aerosolized vesicle fluid or through the respiratory route, 
VZV first replicates in epithelial cells of the upper respiratory 
mucosa. A disseminated vesicular rash appears subsequently 
after an incubation period of approximately 10–21 days. After 
primary infection, immunity to VZV is established, while the 
virus travels by retrograde spread along sensory neurons to 
the trigeminal and dorsal root ganglia establishing a lifelong 
latency (2). In elderly people or immunocompromised patients, 
a reduction in the ability of an appropriate immune response 
could lead to reactivation of VZV from latency allowing the 
virus to travel antegradely from the sensory ganglia to the skin 
nerve terminals and spreading to skin epithelial cells leading 
to the clinical signs of herpes zoster (HZ) (1). Although the 
symptoms of HZ normally resolve within 2–4 weeks, about 10% 
of patients develop postherpetic neuralgia (PHN)—the most 
frequent chronic complication of HZ. PHN is defined as pain 
persisting more than 3 months after the onset of the rash in the 
same affected area. It can interfere with the patients’ sleep and 
daily activities, causing a major loss of quality of life (3). In a 
systematic review including 130 studies conducted in 26 coun-
tries, the incidence rate of HZ was calculated at 3–5 per 1,000 
person-years in North America, Europe, and Asia-Pacific, with 
a notable rise in persons over 50 years of age, reaching 8–12 per 
1,000 person-years at age 80 years. The authors also reviewed 
the risk of developing PHN in patients with HZ and found it to 
range between 5 and 30%, with more than 30% of patients with 
PHN experiencing persistent pain for more than 1 year (4). Age 
is therefore an important risk factor for HZ. Several studies sug-
gested increasing trends of HZ incidence over the past decade, 
which also lead to an increase in the prevalence of PHN, but the 
reasons for these trends are currently still unknown (5). Even 
more severe complications such as disseminated zoster occur 
mainly in immunocompromised patients. Disseminated HZ is 
usually characterized by vesicles spreading beyond the distri-
bution of the affected dermatome, with the potential to affect 
other organs than the skin, potentially leading to pneumonia, 
encephalitis, and hepatitis with a 5–10% fatality rate (6).
Primary VZV infection induces both humoral and cellular 
immune responses. Several studies suggested that humoral immu-
nity appears later and plays a less prominent role in bridling 
primary VZV infections compared with cellular immunity. This 
is supported by the fact that children with B  cell deficiencies 
often recover uncomplicated from primary varicella infections, 
while children with T cell deficiencies are at high risk of progres-
sive varicella (7). With regard to prevention of VZV reactivation, 
cell-mediated immunity (CMI) is believed to be more important 
than antibodies, although the mechanisms of protection are not 
fully understood. This is in line with the fact that the numbers of 
VZV-specific T cells decrease, whereas anti-VZV-immune glob-
ulin G (IgG) titers remain relatively stable over time (8, 9). Another 
study showed that in the first week after HZ rash onset, greater 
VZV CMI responses correlated with lower severity of disease, 
while VZV antibody responses did not correlate with severity 
of HZ or PHN (10). Type I interferons (IFNs) including IFN-α 
and IFN-β dominate the innate defense system against virus 
infections. During VZV replication in the skin after reactivation, 
the signal transducer and activator of transcription 3 is activated 
by VZV in infected cells, thereby suppressing the expression of 
INF-α and STAT1, whereas surrounding uninfected cells show 
upregulation of IFNs and STAT1 (2). Besides, type I and type III 
IFNs can induce the Janus kinase-signal transducer and activator 
of transcription (JAK/STAT) pathway, which leads to phospho-
rylation of STAT1 and STAT2 followed by IFN-stimulated genes 
expression. Verweij et  al. demonstrated that VZV was able to 
inhibit type I IFN-activated signal transduction by degrading 
IFN regulatory factor 9 and inhibiting STAT2 phosphorylation 
of the JAK–STAT pathway (11). Due to the lack of robust models 
for latency, the mechanisms for VZV latency and subsequent 
reactivation are still being poorly understood. Sadaoka et  al. 
established an in  vitro system which recapitulates elements of 
VZV latency and reactivation in  vivo (12). C-Jun N-terminal 
kinase (JNK) pathway was found to play a critical role in the 
viral reactivation using this system and pharmacologic blockade 
of the JNK pathway could inhibit VZV gene expression, lytic 
replication, and reactivation (13). A better understanding of the 
mechanisms underlying VZV reactivation and infection, and 
how the adaptive immune system can effectively protect during 
this process, is still largely unknown and an important topic for 
future investigations.
Transplantation is the only curative therapeutic option for 
terminal organ failure. In recent years, the number of solid organ 
transplant (SOT) and hematopoietic stem cell transplant (HSCT) 
recipients is continuously increasing. For example, about 29,000 
SOTs in the U.S. and 19,000 HSCTs worldwide are performed 
annually (14). The development of novel immunosuppressive 
agents and better diagnosis of graft rejection have dramatically 
improved survival of transplant patients (15). Transplant patients 
are, however, at increased risk for developing HZ and related 
complications due to the need for lifetime immunosuppression. 
The type of transplantation, immunosuppression, and antiviral 
prophylaxis may influence HZ incidence. According to several 
trials and retrospective studies published in the last decade, 
incidence of HZ varied between 3.5 and 9% in kidney (16–20), 
6.9 and 7.2% in liver (18, 21), 11.6 and 14.3% in lung (22–24), and 
16.2 and 16.3% in heart (18, 25) transplant recipients (Table 1). 
Overall, liver transplant recipients have a lower incidence of 
HZ, possibly due to their relatively resistance to rejection and 
less requirement of immunosuppression compared with other 
organ recipients, whereas heart and lung transplants had a high 
rate of HZ possibly explained by the high doses of continuous 
immunosuppression (18, 26).
In this article, we have performed a narrative review of the 
literature in recent years, providing an in-depth analysis of the 
development of diagnosis, treatment, and prevention of HZ, and 
retrospected efficacy and safety of the two currently licensed 
zoster vaccines in immunocompromised adults, with a focus 
on transplant patients (Figure 1). This paper aims to emphasize 
TAbLe 1 | The incidence of herpes zoster (HZ) in transplant patients.
Reference Type of transplantation No. of patients No. of patients who 
developed HZ
Crude incidence of HZ (%) Calculated incidence of HZ 
(cases/1,000 person-years)
(16) Kidney 612 37 6 28
(17) Kidney 1,139 40 3.5 a
(18) Kidney 500 45 9 24.4
Liver 461 32 6.9 18.3
Heart 80 13 16.3 40
(19) Kidney 450 29 6.4 20.6
(20) Kidney 444 35 7.9 a
(21) Liver 377 27 7.2 17.83
(22) Lung 239 29 12.1 55.1
(23) Lung 198 23 11.6 a
(24) Lung 119 17 14.3 38.2
(25) Heart 314 51 16.2 31.6
aThe reference did not show this data.
FigURe 1 | Treatments and prevention of varicella and herpes zoster (HZ).
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the dangerous situation of transplant patients facing HZ and 
the importance of future clinical trials about safety and efficacy 
of zoster vaccines in these HZ high-risk populations.
DiAgNOSiS
Generally, both primary varicella and HZ have typical clinical 
presentations that allow for a presumptive clinical diagnosis 
(26). Primary varicella rash (initially macular, proceeding to 
fluid-filled vesicles then turning yellow pustular) occurs on the 
trunk and face, and spreads to involve much of the skin surface 
(27). The diagnosis of HZ is based on the characteristic cutaneous 
eruption, which always presents as erythematous vesicular rash 
following dermatomal distribution with localized neurological 
pain (26).
Diagnosis of HZ in transplant patients is clinically often 
difficult, because HZ in these patients is more likely to present 
as atypical mucocutaneous forms that could mimic other 
cutaneous diseases, such as herpes simplex virus (HSV) infec-
tion and drug reactions (28), and may present with multiorgan 
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involvement. It rarely develops into invasive complications 
with delayed or absent rash (26). In case of diagnostic uncer-
tainty, laboratory testing [polymerase chain reaction (PCR)] is 
suggested and is becoming the standard for confirmation in 
transplant patients (29).
Viral culture and direct immunofluorescent assay (DFA) are 
the conventional methods for detecting VZV and have long 
been considered the gold standards. However, both methods 
have limitations such as time-consuming, insensitivity, and lack 
of standardization (30), and DFA also requires great technical 
expertise and has a high probability to mistakes in specimen 
collection and storage conditions (31).
Polymerase chain reaction is the most sensitive test for VZV 
and different PCR-based methods have been introduced to the 
clinical laboratory, for example, conventional PCR, nested PCR, 
and real-time PCR (32). PCR can detect VZV virus in vesicle 
fluid swab, biopsies, cerebrospinal fluid (CSF), intraocular flu-
ids, and blood samples (29). Among these, multiplex real-time 
PCR assays can simultaneously detect VZV and HSV in CSF 
and lesion swab specimens in a single test (33). The multiplex 
assay provides accurate and rapid diagnostic capabilities for the 
diagnosis and differentiation of HSV and VZV infections with 
lower costs (34).
In all transplant patients, VZV-specific antibody levels should 
be determined by serologic testing to document prior exposure 
to VZV during their pre-transplant evaluation process. The 
VZV-specific antibodies level can be used for evaluation of the 
post-transplant risk of seronegative patients developing chicken-
pox and seropositive patients developing HZ (26). Determination 
of an increase in anti-VZV IgG and IgM and measurement of 
VZV DNA in CSF or peripheral blood by PCR are the methods 
to confirm diagnosis of HZ sine herpete (defined as dermatomal 
distribution pain occurring without an antecedent rash) (28, 29). 
Antibody tests for VZV include the fluorescent antibody to 
membrane antigen (FAMA), enzyme immunoassay, and enzyme-
linked immunosorbent assays (ELISA). These tests use whole 
antigens of the virus or antigen extracted from VZV-infected 
cell cultures, whereas other tests use the external glycoproteins 
[glycoprotein E (gE), gB, and gH] as antigens, such as the gpE-
LISA (35). FAMA is highly sensitive and considered the gold 
standard test for VZV antibodies, but is labor intensive and not 
automated (36). ELISA is widely used because of its simplicity 
and the possibility of automation, but still lacks sufficient sensi-
tivity of detecting vaccine seroconversion (37). Combination of 
serology testing and real-time PCR on paired serum and CSF/
intraocular fluid can be used for diagnosing HZ with cerebral and 
ocular complications (38). It is important to develop new precise 
assays because false-negative and false-positive results due to 
limitations of serologic testing may lead to unnecessary vaccina-
tions or therapy (35). Even more important is the limitation that 
antibody titers do not necessarily correlate with protection. It is 
unknown whether high antibody titers are correct correlates of 
VZV protection or only a measure of past infection. Seemingly 
protective antibody titer in a whole virus ELISA may not correlate 
with protective levels of antibodies directed against membrane 
antigens (39). Development of methods to determine potential 
HZ-predisposing VZV-specific cellular adaptive immunity could 
be promising for the future, because VZV-specific antibodies 
only have an apparent limited protective effect (24).
TReATMeNT
Herpes Zoster
The primary goals for the treatment of HZ by taking antiviral 
agents are to control the replication of VZV in infected cells and 
to soothe and protect the infected skin. Lowering the chance of 
accompanying complications is also a major treatment goal in 
transplant patients. It is recommended to initiate administration 
of antivirals in patients with HZ within 72  h after cutaneous 
symptoms onset, or at a later time. Administration as early as 
possible can decrease the intensity and duration of zoster-
associated pain, prevent dissemination and fulminant visceral 
involvement, accelerate the healing of skin lesions, and improve 
the affected patients’ quality of life. Antiviral agents can still be 
administered in certain patients who present >72  h after the 
onset of skin symptoms. These patients include elderly patients 
over 60 years of age with severe pain and HZ in large affected 
skin areas, patients with persistent new vesicle formation, or 
immunocompromised patients, and in those with complicated 
HZ (28). Antiviral therapy can be stopped when no more new 
vesicles appear. If vesicle formation sustains during treatment 
over 7  days, the diagnosis should be re-evaluated, and drug 
resistance may be a problem (40).
The synthetic nucleoside analog of guanine acyclovir and its 
prodrug valacyclovir, penciclovir’s prodrug famciclovir, and the 
thymidine analog brivudin are the most widely used drugs for 
the HZ antiviral treatment (1). When choosing an antiviral drug, 
all possible factors influencing efficacy should be considered, 
including routes of administration, dosage frequency, costs, 
complications contraindications, and drug interactions (40).
Acyclovir
Acyclovir was the first drug discovered that had antiviral activity 
against herpes virus and is very safe and well tolerated (41). HZ 
in immunocompetent patients can be treated orally, but due to 
the poor oral bioavailability (15–30%) of acyclovir, other simpler 
dosing and better pharmacokinetic antiviral drugs (valacyclovir 
or famciclovir) are preferred (1, 42). Intravenous acyclovir with 
500 mg/m2 every 8 h is the initial therapy of choice for a varicella-
like rash in SCT recipients. When the infection is controlled, 
oral antiviral medication is an option for the remainder of the 
treatment (43).
Valacyclovir
Valacyclovir is a prodrug of acyclovir with three to five times 
higher oral bioavailability than acyclovir (44), and it was approved 
for use as an additional treatment for herpes virus infections in 
the USA in 1995 (45). The convenient dosing schedule (1,000 mg 
three times daily) and quicker cessation of pain makes valacy-
clovir more efficacious than acyclovir in treating acute HZ (46).
Famciclovir
Famciclovir is a well-absorbed (bioavailability 77%) first-line 
option for the treatment of HZ and used for treating HZ in 
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immunocompetent adults and immunosuppressed patients older 
than 25 years, but not approved in childhood and adolescence 
(1). In a study with 148 patients who were immunocompro-
mised following bone marrow or solid organ transplantation or 
oncology treatment, the efficacy and safety of famciclovir was 
evaluated. The study showed that oral famciclovir is convenient, 
effective, and well tolerated for immunocompromised patients 
with HZ (47).
Brivudin
Brivudin is a thymidine nucleoside analog with stronger anti viral 
effect against VZV than reference compounds such as acyclovir 
by blocking the action of DNA polymerases. Oral brivudin 
(125 mg once daily) is licensed for the treatment of HZ in several 
countries of the European Union (48). In a double-blind rand-
omized multicenter study, 48 immunocompromised patients 
with a HZ rash less than 72 h in duration received brivudin or 
intravenous acyclovir treatment. No significant difference was 
seen regarding cutaneous or visceral dissemination compared 
between the two therapies (49). Brivudin is not available in all 
countries and not approved for antiviral therapy in children and 
adolescents due to lacking of studies about safety profile (1, 40).
Antiviral Agents Used to Treat Herpes Viruses Other 
Than VZV and Co-Infections
Ganciclovir and its valyl-ester valganciclovir, and foscarnet are 
primarily used to treat cytomegalovirus (CMV) infections (50). 
Both agents are nevertheless active against VZV and may be 
used to treat double infections or to suppress reactivations (51).
Although foscarnet dosing to treat VZV has not been studied 
extensively, doses required to treat CMV infections have been 
shown to treat VZV successfully. Foscarnet, however, is consider-
ably more toxic than acyclovir. It is only recommended for the 
treatment of CMV co-infections, or when antiviral resistance is 
suspected (52).
Likewise, ganciclovir and valganciclovir are largely used for 
the treatment of CMV infections, but both agents possess excel-
lent activity against VZV in doses used to treat CMV infections 
(51). Its toxicity especially to bone marrow restricts its use to 
prophylaxis and treatment of CMV co-infections (53, 54).
Postherpetic Neuralgia
Postherpetic neuralgia tends to be underdiagnosed and inad-
equately managed, so treatments of PHN are palliative and short-
ening of duration and severity of pain is the main goal of PHN 
management (55, 56). According to the guidelines (2010) issued 
by the European Federation of Neurological Societies, tricyclic 
antidepressants (TCAs), antiepileptics (gabapentin/pregabalin), 
and topical lidocaine plaster (5%) are recommended as first-line 
treatment in PHN (57).
Tricyclic Antidepressants
Tricyclic antidepressants, including two classes—the secondary 
amines (nortriptyline and desipramine) and the tertiary amines 
(amitriptyline and imipramine)—have been commonly used for 
the treatment of PHN from the early 1980s (55). TCAs can block 
voltage-dependent sodium channels and α-adrenergic receptors 
and also inhibit the reuptake of monoaminergic transmitters 
which can enhance the effects of biogenic amines in modulat-
ing descending pain pathways (58). Clinical experience showed 
TCAs to be effective in the control of PHN and amitriptyline 
is the most commonly used TCAs which can improve patients 
sleep more due to its sedating property. However, TCAs are 
often poorly tolerated with a relatively slow onset of action 
and associated with systemic adverse events (AEs) such as dry 
mouth, constipation, serotonin syndrome, cardiotoxicities, and 
anticholinergic effects. TCAs side effects are common in the 
mostly elderly population afflicted with PHN thus alternative 
treatments may be considered (3).
Antiepileptics
Oral antiepileptics gabapentin and pregabalin can block voltage-
sensitive calcium channel, decrease the release of several neuro-
transmitters, and inhibit central pain pathways. In clinical trials, 
gabapentin and pregabalin significantly reduced PHN-related 
pain and improved sleep quality more than placebo (59, 60). 
Gabapentin may be superior to other formulations in terms of 
compliance and safety, while pregabalin was associated with 
better health outcomes and cost-effectiveness (60, 61). The most 
common side effects of gabapentin and pregabalin are dizziness, 
somnolence, and peripheral edema (62, 63). These AEs could 
limit their use in some patients.
Lidocaine Plasters (5%)
Lidocaine-medicated plasters (LMP) were approved to use in 
the treatment of PHN by the Food and Drug Administration 
(FDA) in 1999 and have been licensed in several European, Latin 
American, and the Middle East countries since then (64). As a 
topical analgesic, 5% LMP can deliver the drug directly to the site 
of pain and provides local pain relief through localized analgesia, 
without inducing anesthesia or numbness (64). In a systematic 
review including 20 unique studies, 5% LMP showed similar 
effects on pain relief compared with gabapentin and was more 
effective than placebo, capsaicin, and pregabalin (change in pain 
from baseline) (65). 5% LMP is more cost-effective than prega-
balin in a UK setting (66) and demonstrated good short- and 
long-term tolerability with a minimal risk for systemic adverse 
drug reactions (67).
Polypharmacy
Because monotherapy may not be sufficient of modifying all of 
the complex pain mechanisms that underlie PHN, combination 
therapies are frequently applied and five or more drugs on average 
are taken by a typical PHN patient (56). Due to the low tendency 
of gabapertinoids and topical analgesics for interactions with 
other drugs, they have become the most attractive agents for com-
bination therapies (55). A randomized, open-label, multicenter, 
non-inferiority study indicated that combination of pregabalin 
and 5% LMP provided additional efficacy for pain relief in PHN 
in patients unresponsive to either monotherapy (68).
Concerning transplant patients, their complicated condition 
and weak organ function such as renal impairment, could affect 
drug metabolism and tolerability (69). In the setting of polyphar-
macy, it would be more difficult to choose and dosage would also 
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change according to every patient’s situation, while side effects of 
different drugs should also be considered. Besides, once patients 
develop PHN after HZ, the condition does not usually adequately 
respond to treatment (70).
PReveNTiON/PROPHYLAXiS
vaccination
Current treatment strategies for HZ and PHN are only partially 
effective, so reducing the burden of HZ by prophylactic vacci-
nation may be a proactive strategy (71).
Live-Attenuated Zostavax® (Merck, USA)
In 2006, the FDA approved the 1-dose live-attenuated HZ vaccine 
Zostavax® for use in individuals 60 years of age and older and 
expanded the use of Zostavax® among adults aged 50 through 
59 years in March 2011 (72). In 2017, the Advisory Committee 
on Immunization Practices (ACIP) reviewed their guidelines 
and Zostavax® remained as a recommended vaccine for immu-
nocompetent adults aged over 60 years to prevent HZ (73).
Zostavax® contains at least a 14 times higher titer of the same 
live-attenuated Oka/Merck strain used in the varicella vaccine 
(Varivax®, a live-attenuated varicella vaccine for the preven-
tion of chickenpox) and is therefore only recommended for 
VZV seropositive people (74). Several studies have shown the 
efficacy of Zostavax® in HZ and PHN prevention. The Shingles 
Prevention Study (SPS) was a randomized, double-blind, 
placebo-controlled study that enrolled 38,546 adults over the 
age of 60 years and showed that Zostavax®, respectively, reduced 
the incidence of HZ and PHN by 51.3 and 66.5% in 4 years of 
postvaccination follow-up. However, the efficacy against HZ 
incidence decreased with age (37.6% among subjects ≥70 years 
old and 63.9% among younger subjects) (75, 76). To further 
assess the persistence of vaccine efficacy, the Short-Term and 
Long-Term Persistence Substudy were undertaken following 
SPS. The STPS re-enrolled 14,270 SPS vaccine and placebo 
recipients, and after 5 years, vaccine efficacies for HZ burden 
of illness, the incidence of PHN, and the incidence of HZ 
decreased from 61.1 to 50.1%, 66.5 to 60.1%, and 51.3 to 39.6%, 
respectively (77). In the LTPS, vaccine efficacy declined for all 
these three outcome measures from 7 to 11 years postvaccina-
tion (78). To reverse this decline in efficacy, a booster dose of 
Zostavax® could be a potential solution. HZ vaccine was given 
as a second dose to 200 subjects over the age of 70 years who 
had received one dose Zostavax® ≥10 years before in a study, 
and the VZV-specific cellular and humoral responses to this 
booster dose were compared with older and younger vaccinee. 
This study showed that while VZV antibody levels were similar 
in all age groups, VZV-specific CMI was significantly higher in 
the booster-dose group. The authors suggested that more clini-
cal trials of appropriate age of vaccine administration as well as 
the potential of booster dose would be required (79).
Because post-transplantation, humoral and cellular respon ses 
to vaccines are suboptimal, it is important to immunize patients 
while they are awaiting transplantation. This should optimally be 
part of a comprehensive pre-transplant evaluation and prepara-
tion (80). Zostavax® is contraindicated after transplantation, 
because of the increased risk for live vaccine-induced infections, 
caused by the altered immunocompetence. According to the 
2008 ACIP guideline, zoster vaccine should be administered at 
least 14  days before initiation of immunosuppressive therapy. 
Zoster vaccine is recommended in HSCT candidates over 
4 weeks before transplantation but contraindicated after HSCT 
due to limited experience of HSCT recipients with life VZV-
containing vaccines (14). Vaccination may be considered after 
assessing of the immune status of the recipient on a case-by-case 
basis and only administered at least 24 months after HSCT (81).
A study retrospectively assessed the use of Zostavax® in 62 
patients with hematologic malignancy. Among them, 31 patients 
received hematopoietic cell transplant (HCT), and the median 
times to vaccination post-transplant were 482 days (26 patients 
received autologous HCT) and 1,323  days (5 patients received 
allogeneic HCT). There were no documented AEs associated 
with administration of Zostavax® among all the patients. One 
patient developed HZ 3 weeks after vaccination, but they could 
not establish whether this was caused by wild-type VZV or the 
Oka/Merck strain because genotyping data were not included in 
this study (82). In another study, a single dose of Zostavax® was 
given to 110 adult autologous and allogeneic HSCT recipients 
about 2  years post-transplantation. Two patients developed a 
skin rash with unclear reason after vaccination and 98.2% of 
vaccine recipients had no AEs within a median 9.5  months 
follow-up period (83). In a retrospective study about the safety 
of measles–mumps–rubella (MMR) vaccine and Zostavax® in 
multiple myeloma patients about 24  months after autologous 
HCT, 70 patients on maintenance lenalidomide received one 
dose HZ vaccine (69 patients also received MMR vaccine). No 
rash or other AEs related to the vaccines were identified and 
one patient with previous PHN history experienced worsening 
pain without rash while the reason leading to this situation was 
unknown (84). Miller et  al. conducted a randomized, placebo-
controlled study, which enrolled 34 participants with end-stage 
renal disease awaiting renal transplantation (26 subjects received 
one dose Zostavax® and 8 received placebo). From 30 to 235 days 
after vaccination, 14 subjects underwent transplantation and 12 
of them received zoster vaccine. There were no zoster rashes or 
reactogenicity events associated with vaccine that happened to 
subjects (85). Though limitations exists, including small sample 
size and lacking of longer follow-up, these studies show a poten-
tial benefit of HZ vaccine in transplant patients before and after 
the transplantation with a good safety profile. Larger, controlled 
studies are needed to further explore the safety and efficacy of 
Zostavax® in HCT and SOT population (82, 83).
The HZ Subunit Vaccine (HZ/su, Shingrix®)
Subunit vaccines can provoke a strong immune response, while 
being a safe vaccine for transplant patients, because they avoid 
the risk of disease caused by replication of the vaccine virus (86).
A new recombinant subunit vaccine (Shingrix®) contain-
ing VZV gE and the AS01B adjuvant system was tested by 
GlaxoSmithKline in 2015. In a phase III randomized study 
including 15,411 participants (≥50 years of age) from 18 coun-
tries, two doses of the HZ/su administered 2 months apart had 
a vaccine efficacy of 97.2% and significantly reduced the HZ 
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in adults 50  years of age or older (87). HZ/su also had a vac-
cine efficacy of 89.8% in adults over 70  years old and showed 
no decline in efficacy with age (88). Besides, a follow-up, mul-
ticenter, single group trial conducted in the Czech Republic, 
the Netherlands, Germany, and Sweden indicated that both 
gE-specific cellular and humoral immune responses decreased 
over time but remained substantially above prevaccination levels 
for up to 6 years in healthy older adults who had received two 
doses of HZ/su. HZ/su seems to have the potential to provide 
long-term protection against HZ in older adults (89). Solicited 
reports of injection-site and systemic reactions such as fatigue 
and myalgia were more among HZ/su than placebo, but the 
reactions were generally mild-to-moderate in intensity and 
serious AEs and deaths were similar in the vaccine and placebo 
groups (87–89). A cost-effectiveness analysis using Markov 
decision model compared HZ subunit vaccine, Zostavax® or 
no vaccination in immunocompetent adults ≥60 years old. The 
schedule with two doses HZ/su (at a price of $280 per  series) 
was found to be more effective and at lower costs than Zostavax® 
(90). Shingrix® was approved by FDA for the prevention of HZ 
in adults older than 50 years old and recommended by ACIP for 
use in immunocompetent adults aged ≥50 years in October 2017. 
ACIP also made the comment that Shingrix® is recommended 
for immunocompetent adults who received live-attenuated HZ 
vaccine before and Shingrix® is preferred over Zostavax® for the 
prevention of HZ and related complications (73).
With regard to transplant patients, so far there is only one 
published study about the HZ/su in autologous HCT recipi-
ents. In this phase I/II, randomized, observer-blind, placebo-
controlled study, three-dose regimen was found well tolerated 
and immunogenic in adults who had undergone autologous 
HSCT 50–70  days earlier. Both humoral and cellular immune 
responses were strong and persisted for up to 1  year postvac-
cination. Although with annotated limitations of small numbers 
of subjects and requirements for additional follow-up, the result 
shows a promising prospect for immunization of transplant 
patients (91). More studies especially phase III follow-up trials 
are still needed. Finally, a phase III trial assessing the efficacy of 
HZ/su in autologous stem cell transplant patient is under way 
and phase I/II trials in SOTs are in progress (92).
Antiviral Agents
Long-term acyclovir/valacyclovir prophylaxis to prevent 
recurrent VZV infection is routinely recommended by the 
2009 International Guidelines for the first year after HCT for 
VZV-seropositive allogeneic (should generally be offered) and 
autologous (optional) HCT recipients (93). In a systematic review 
including six observational studies involving 3,420 HSCT recipi-
ents, the optimal duration of antiviral prophylaxis (acyclovir, 
valacyclovir, and famciclovir) for preventing HZ was analyzed. 
It was found that antiviral prophylaxis may significantly decrease 
the reactivation of VZV in HSCT recipients and patients taken 
antiviral prophylaxis at least 1 year compared with less than 1 year 
showed lower incidence of HZ (2.1 and 15.4%, respectively) (94). 
In SOT recipients, prophylaxis such as acyclovir has not been 
systematically studied (26). Koo et al. reviewed the medical files 
of 314 heart transplant recipients from 1995 to 2010. 134 patients 
received ganciclovir/valganciclovir-based CMV prophylaxis for a 
median of 143 days post-transplantation. The majority of patients 
develop VZV infection during the first post-transplant year 
and the risk of HZ decreased with ganciclovir or valganciclovir 
prophylaxis (25). In another study including 444 adult kidney 
transplants, administering anti-CMV prophylaxis (ganciclovir/
valganciclovir) for 3–6 months after transplantation reduced the 
risk of HZ and no patients developed HZ during CMV antiviral 
prophylaxis (20). Although antiviral prophylaxis is effective for 
preventing HZ, the risk of VZV reactivation is still much higher 
in transplant patients than the general population (20, 95, 96). 
It is also difficult to completely prevent the development of HZ 
after the discontinuation of prophylaxis. Once prophylaxis was 
discontinued, the cumulative risk for developing VZV disease 
remained high (95, 97). Besides, the emergence of resistant VZV 
strains due to long-term prophylaxis is also a potential risk that 
cannot be neglected despite no antiviral agent-resistant VZV was 
observed so far (97).
Post-exposure Prophylaxis (Seronegative 
Patients Only)
Varicella-zoster immune globulin (VZIG) is a purified human 
IgG with high titers of antibodies to VZV and used to provide 
passive immunization for seronegative patients exposed to VZV 
(98). In December 2012, FDA approved a VZV immune globulin 
preparation VariZIG (Cangene Corp., Winnipeg, MB, Canada) 
for use in the U.S. as a post-exposure prophylaxis of varicella 
(99). In July 2013, the Centers for Disease Control and Prevention 
(CDC) updated recommendations for use of VariZIG. The CDC 
recommended that patients without evidence of immunity to 
varicella who are at high risk for severe varicella and complica-
tions should receive VariZIG as soon as possible after exposure to 
varicella-zoster virus and within 10 days. Patient groups recom-
mended by CDC to receive VariZIG include the following:
 (1) immunocompromised patients without evidence of 
immunity;
 (2) newborn infants whose mothers have signs and symptoms 
of varicella around the time of delivery (i.e., 5 days before to 
2 days after);
 (3) hospitalized premature infants born at ≥28 weeks of gesta-
tion whose mothers do not have evidence of immunity to 
varicella;
 (4) hospitalized premature infants born at <28 weeks of gestation 
or who weigh ≤1,000 g at birth, regardless of their mothers’ 
evidence of immunity to varicella; and
 (5) pregnant women without evidence of immunity (99).
So far, there is a lack of evidence in prior studies about the use of 
VZIG to prevent severe varicella, HZ, and relevant complications 
in SOT patients, and most reports about successful use of VZIG are 
in pregnant women and infants. In a study form Denmark involv-
ing 104 pregnant women who received VZIG from December 
2005 to March 2015, only five (6%) women developed varicella 
during VZIG treatment and VZIG seems effective in preventing 
varicella and zoster (100). In a retrospective record review of 812 
adult renal transplant recipients, performed from 1995 until 2004 
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in a single center, eight patients developed varicella infection and 
six of these patients received VZIG with acyclovir. There was no 
significant impact of the use of VZIG on the clinical spectrum of 
the disease and the authors concluded that passive immunization 
with VZIG is useless once clinical varicella has already established, 
a finding that is in agreement with other studies (101). Due to the 
high cost and short supply of VZIG in some, alternative approach 
of prophylaxis using antiviral agents or vaccination against VZV 
is needed (43, 102, 103).
PROSPeCT
Despite great advances in transplantation in recent decades, 
infection still is a major cause of morbidity and mortality among 
transplant recipients. Transplant patients are at high risk for 
developing HZ and accompanying complication such as PHN 
and disseminated cutaneous disease (14, 18, 104). In addition, 
treatments for transplant patients are more difficult because 
of their complicated conditions and reduced organ function 
(69). Regular screening to evaluate each patient’s humoral and 
cellular immunity against VZV and ensuring early recogni-
tion and preventing HZ by vaccination may be a proactive 
strategy. Currently, there are two licensed HZ vaccine, the 
live-attenuated vaccine Zostavax® and the recombinant subunit 
vaccine Shingrix®. For immunocompetent older people within 
the recommend immunization age, vaccination rate is still low 
in the U.S. In a retrospective observational study conducted in 
2015, 6,746,476 U.S. adults aged ≥60 years during 2007–2013 
and 6,770,294 adults aged 50–59 years during 2011–2013 were 
identified as vaccinated. This study found that 19.5% of adults 
aged ≥60  years received an HZ vaccine, which is lower than 
the 30% target of Healthy People 2020 (including objectives 
designed to serve as this decade framework for improving the 
health of all people in the U.S.) (105). For transplant patients, 
HZ vaccine usage after transplantation is still contraindicated 
in this population due to its live-attenuated characteristic. 
Pre-transplantation immunization is considered a relevant 
alternative, but efficacy of protection after transplantation still 
needs to be established. Both HZ vaccines have been tested in 
autologous HCT recipients and showed promising safety and 
efficacy (Table 2). Shingrix® is a candidate for a post-transplant 
vaccine as it does not contain any live virus. Larger, prospec-
tive, controlled studies are warranted to further determine the 
safety and efficacy of Zostavax® and Shingrix® in transplant 
TAbLe 2 | Herpes zoster (HZ) vaccine usage in transplant patients.
Reference vaccine Number and type  
of patients
Median time to vaccination  
pre/post-transplantation
HZ after vaccination Adverse events (Aes)
(82) Zostavax® 62 patients with hematologic 
malignancy: among them 26 
(41.9%) underwent autologous 
hematopoietic cell transplant  
(HCT); 5 (8.1%) underwent 
allogeneic HCT; 31 (50%)  
without HCT
482 days after autologous HCT; 
1,323 days after allogeneic HCT
One patient underwent autologous 
HCT developed HZ 3 weeks after 
vaccination and was treated with 
10 days of high dose acyclovir
No documented AEs
(83) Zostavax® 52 patients underwent autologous 
hematopoietic stem cell transplant 
(HSCT); 58 patients underwent 
allogeneic HSCT
27 months after HSCT One patient underwent  
autologous HSCT developed a  
skin rash 10 days after vaccination. 
One patient underwent allogeneic 
HSCT developed a vesicular skin 
rash 24 days after vaccination  
and was treated with valacyclovir
108 (98.2%) patients had  
no clinically apparent AEs
(84) Zostavax® 70 multiple myeloma patients on 
maintenance lenalidomide with 
autologous HCT: among them 69 
patients also received measles–
mumps–rubella vaccination
25 months after HCT Two patients developed a non-
specific rash requiring no therapy 
and resolved by themselves
Upper respiratory tract infection 
is the most common AE  
(10/70 patients)
One patient with pre-existing 
postherpetic neuralgia (PHN) 
experiencing worsening of PHN 
without development of a rash
(85) Zostavax® 26 patients with end-stage 
renal disease awaiting renal 
transplantation: among them  
12 (46%) received transplantation
From 30 to 235 days before 
transplantation
No zoster rashes happened Local reactogenicity symptoms 
occurred in 9 subjects (35%).  
No AEs associated with vaccine
(91) Recombinant 
HZ vaccine
120 patients underwent  
autologous HCT: 30 patients 
received 3 doses of gE/AS01B; 29 
patients received 3 doses of  
gE/AS01E; 31 patients received  
2 doses of gE/AS01B; 30 patients 
received 3 doses of saline
Patients underwent HCT  
in the previous 50–70 days
Two patients in the 3 doses of  
gE/AS01E and two patients in  
the saline group developed HZ
Most subjects experienced 
solicited local and general 
reactions of mild or moderate 
intensity
One patient in the 2 doses of  
gE/AS01B group had serious  
AE (pneumonia) and was 
considered vaccine related
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